Key takeaways:
Participants at HJF Medical Research International in Abuja, Nigeria, have been vaccinated in the first Phase 2 clinical trial of a Lassa fever virus (LASV) vaccine candidate to date, according to IAVI, a nonprofit scientific research organization and the trial sponsor. The study (IAVI C105/PREVAIL15) is funded by CEPI, an innovative global partnership working to accelerate the development of vaccines against epidemic and pandemic threats.
The trial in Nigeria has been designed in consultation with in-country partners, including the Nigeria Centre for Disease Control and Prevention and the Nigeria Lassa Vaccine Taskforce. HJF Medical Research International, Ltd/Gte (HJFMRI) has been conducting infectious diseases research in collaboration with HJF and the Walter Reed Army Institute of Research in Nigeria since 2014. In addition to Nigeria, and pending regulatory approval, IAVI expects to enroll additional participants at the Noguchi Memorial Institute for Medical Research (NMIMR), College of Health Sciences, University of Ghana, and the Partnership for Research on Vaccines and Infectious Diseases in Liberia (PREVAIL)[1].
Nigerian clinicians, scientists andcommunity membersare key leaders in this international collaboration, which will ensure that vaccine development incorporates local context, experience and perspectives while fostering sustainable in-country research capacity and partnerships, said Dr. Abdulwasiu Bolaji Tiamiyu, clinical research center director, HJFMRI, and principal investigator of IAVI C105 in Nigeria.
No approved vaccine currently exists for LASV, which causes an acute viral hemorrhagic illness called Lassa fever. Given its potential to cause a public health emergency of international concern, LASV is included in the World Health Organization R&D Blueprint of priority pathogens for which there is an urgent need for accelerated research and development (R&D) and countermeasures[2]. IAVI and members of the global Viral Hemorrhagic Fever Consortium have been collaborating since 2018 to accelerate clinical development of IAVIs single-dose LASV vaccine candidate in studies supported and funded by CEPI and the European & Developing Countries Clinical Trials Partnership (EDCTP). Read more.
An estimated 5,000 people die each year from LASV, and about 300,000 people fall ill across West Africa annually though the true disease burden is thought to be much higher. Nigeria, Liberia, Sierra Leone, and Guinea are most affected, but increasingly, neighboring countries are experiencing their own emerging outbreaks, with travelers occasionally carrying infections to other regions. Although most people who develop LASV have mild or no symptoms, approximately 20% will develop more serious symptoms including widespread bleeding and major organ failure. Approximately a third of those infected with LASV experience associated deafness, sometimes resulting in lifelong disability. Children under 10 years old, pregnant people, and health care workers are especially vulnerable to LASV infection.
Continued outbreaks of Lassa fever and the emergence of Ebola Sudan in Uganda both underscore the need to have vaccines for known disease threats available for evaluation and use during outbreak situations the overarching goal of IAVIs emerging infectious disease program. said Swati Gupta, DrPH, MPH, vice president and head of emerging infectious diseases and epidemiology, IAVI. IAVI C105 is an important step toward attaining eventual licensure of a Lassa fever vaccine, should IAVIs vaccine candidate prove to have an acceptable safety profile and be efficacious. We are grateful to our funders, our clinical partners, and our consortium collaborators for their continued support of IAVI and commitment to a more secure world.
Lassa fever has long been a threat to much of West Africa, and factors like climate change and population growth could exacerbate its transmission in coming decades, explainsDr. Richard Hatchett, CEO of CEPI. The world urgently needs a Lassa vaccine for routine immunization. The initiation of IAVIs new Phase 2 trial the most advanced Lassa vaccine trial to date is an important milestone in public health and signals that better tools to manage and prevent outbreaks are coming. We look forward to continuing to collaborate with IAVI and regional partners to advance this promising vaccine as quickly as possible.
IAVIs LASV vaccine candidate was well-tolerated and immunogenic among participants in both the U.S. and Liberian cohorts of IAVIs Phase I LASV vaccine trial (IAVI C102). Robust immune responses appear to be sustained for up to one year after vaccination[3]. In the Phase 2 study, researchers will evaluate the vaccine candidates safety, tolerability, and immunogenicity at two different dosage levels in adults, including people living with HIV, as well as in adolescents and in children two years of age and older. Approximately 612 participants will be enrolled and followed for six months after vaccination to monitor their safety and immune responses. A subset of participants will be followed for an additional two years for extended safety and immunogenicity.
CEPI and IAVI are united in their commitment to global equitable access. Should the candidate be found to be safe and efficacious in clinical testing, IAVI is committed to making its Lassa vaccine affordable and accessible to all populations in need.
Harnessing a proven platform technology for global preparedness
IAVIs LASV vaccine candidate uses the same recombinant vesicular stomatitis virus (rVSV) vector platform as ERVEBO, Mercks single-dose Zaire ebolavirus (ZEBOV) vaccine, which is licensed in North America, Europe, and 10 African countries. The rVSV platform has been used extensively in adults and children[4].
IAVIs goal is to develop and test rVSV-based vaccines against emerging infectious disease pathogens that pose epidemic threats as part of an overall preventive strategy which includes routine immunization as appropriate as well as stockpiles which can be rapidly deployed for larger outbreaks as needed. IAVIs EID portfolio includes a Sudan ebolavirus vaccine candidate supported by BARDA; a Lassa fever vaccine candidate supported by CEPI and EDCTP; a Marburg virus vaccine candidate supported by BARDA and the Defense Threat Reduction Agency (DTRA) of the U.S. Department of Defense (DOD); and an intranasal SARS-CoV-2 vaccine candidate supported by DOD DTRA and the Japan Ministry of Finance.
Much of the R&D on IAVIs rVSV platform is performed at the IAVIVaccine Design and Development Lab(DDL) in Brooklyn, New York. The DDL is one of the worlds leading viral vector vaccine R&D labs, known for innovation and generation of novel vaccine design concepts. Scientists with IAVIsHuman Immunology Laboratory(HIL) in London, U.K., are involved in processing participant samples and developing the analytical assays needed to evaluate IAVI C105 participants immune responses. They are also facilitating technology transfer of the assays to West African partner institutions.
IAVIs LASV vaccine candidate was manufactured byBatavia Biosciencesin Leiden, The Netherlands, a contract-development and manufacturing organization focused on delivering sustainable, low-cost manufacturing solutions in the field of infectious disease and cancer. Through itspartnershipwith Batavia, IAVI intends to develop an end-to-end platform for flexible, low-cost production of epidemic preparedness vaccines.
Results from IAVI C105 are expected in 2025 and will be made available through open-access publications and via scientific meetings to ensure all can benefit from the research.
###
IAVI Media Contact Rose Catlos Rcatlos@iavi.org 212-847-1049
CEPI Media Contact press@cepi.net +44 7387 055214
HJFMRI Media Contact Lisa Reilly lreilly@Global-ID.org 301-339-3566
About IAVI
IAVI is a nonprofit scientific research organization dedicated to addressing urgent, unmet global health challenges including HIV, tuberculosis, and emerging infectious diseases. Its mission is to translate scientific discoveries into affordable, globally accessible public health solutions. Read more atiavi.org.
Follow IAVI on Facebook, LinkedIn, Instagram, and YouTube, and subscribe to our news updates.
About CEPI
CEPI was launched in 2017 as an innovative partnership between public, private, philanthropic and civil organisations. Its mission is to accelerate the development of vaccines and other biologic countermeasures against epidemic and pandemic threats so they can be accessible to all people in need. CEPI has supported the development of more than 50 vaccine candidates or platform technologies against multiple known high-risk pathogens or a future Disease X. Central to CEPIs pandemic-beating five-year plan for 2022-2026 is the 100 Days Mission to compress the time taken to develop safe, effective, globally accessible vaccines against new threats to just 100 days.
About IAVIs rVSV vaccine candidates
IAVI holds a nonexclusive license to the rVSV vaccine candidates from the Public Health Agency of Canada (PHAC). The vector was developed by scientists at PHACs National Microbiology Laboratory.
IAVI initially developed its rVSV vector for HIV vaccine candidates and has since expanded its use to the development of vaccines addressing emerging infectious diseases (Lassa Fever, Marburg, Sudan ebolavirus, and COVID-19).
Funders who have made the development of IAVIs rVSV-vectored vaccine candidates possible include the Bill & Melinda Gates Foundation; the Government of Canada; the Danish Ministry of Foreign Affairs; the Government of Japan; the Irish Department of Foreign Affairs and Trade; the Netherlands Ministry of Foreign Affairs; the Norwegian Agency for Development Cooperation; the U.K. Foreign, Commonwealth & Development Office; the U.S. National Institutes of Health; and through the generous support of the American people from the United States Agency for International Development. This project is funded in whole or in part with federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority under contract number 75A50121C00077.
[1] PREVAIL is aLiberia-U.S. clinical research collaboration established in 2014 by the U.S. National Institute of Allergy and Infectious Diseases (NIAID) and the Ministry of Health in Liberia. In 2015, PREVAIL participated in a clinical trial (PREVAIL 1) of Mercks now-licensed Ebola Zaire vaccine ERVEBO, which uses the same recombinant vesicular stomatitis virus (rVSV) vector backbone as the candidates in IAVIsemerging infectious diseases(EIDs) vaccine development portfolio, including the IAVI LASV vaccine candidate being evaluated ina Phase I clinical trial.
[2] Blueprint (who.int)
[3] https://www.iavi.org/wp-content/uploads/2023/11/C102_ASTMH_Poster_Chicago2023.pdf
Read the original here:
- Booster dose of the Pfizer-BioNTech/BNT162b2 COVID19 vaccine | IDR - Dove Medical Press [Last Updated On: August 9th, 2022] [Originally Added On: August 9th, 2022]
- Monkeypox vaccines have arrived in Victoria. Here's how the rollout will work - ABC News [Last Updated On: August 9th, 2022] [Originally Added On: August 9th, 2022]
- UHD, H-E-B Offering Students Bacterial Meningitis Vaccine On Campus With Deferred Payment Option - UHD News [Last Updated On: August 9th, 2022] [Originally Added On: August 9th, 2022]
- Vaccine effectiveness of two-dose BNT162b2 against symptomatic and severe COVID-19 among adolescents in Brazil and Scotland over time: a test-negative... [Last Updated On: August 9th, 2022] [Originally Added On: August 9th, 2022]
- Japan plans booster shots of Omicron vaccine in October | The Asahi Shimbun: Breaking News, Japan News and Analysis - [Last Updated On: August 9th, 2022] [Originally Added On: August 9th, 2022]
- EyeGene to conduct vaccine projects with government support - KBR [Last Updated On: August 9th, 2022] [Originally Added On: August 9th, 2022]
- Monkeypox Vaccine: Where to Get It - countynewscenter.com [Last Updated On: August 9th, 2022] [Originally Added On: August 9th, 2022]
- Vaccines for Covid-19 arent required in schools this fall - Vox.com [Last Updated On: August 9th, 2022] [Originally Added On: August 9th, 2022]
- 600 in Wisconsin receive monkeypox vaccination, says health department - Green Bay Press Gazette [Last Updated On: August 11th, 2022] [Originally Added On: August 11th, 2022]
- Effectiveness of third vaccine dose for coronavirus disease 2019 during the Omicron variant pandemic: a prospective observational study in Japan |... [Last Updated On: August 11th, 2022] [Originally Added On: August 11th, 2022]
- Why Monkeypox Vaccine Shortage May Threaten the Immunocompromised - The New York Times [Last Updated On: August 11th, 2022] [Originally Added On: August 11th, 2022]
- UK will run out of monkeypox vaccine in 10 to 20 days - The Guardian [Last Updated On: August 11th, 2022] [Originally Added On: August 11th, 2022]
- New method of nasal vaccine delivery could lead to better vaccines for HIV and COVID-19 - UMN News [Last Updated On: August 11th, 2022] [Originally Added On: August 11th, 2022]
- Phillys monkeypox vaccine shortages arent solved yet as feds make move to increase access to the shots - The Philadelphia Inquirer [Last Updated On: August 11th, 2022] [Originally Added On: August 11th, 2022]
- Vaccines are now approved for children aged six months to five years, but what about newborn babies? - ABC News [Last Updated On: August 11th, 2022] [Originally Added On: August 11th, 2022]
- Bottling the monkeypox vaccine could take until early 2023 - POLITICO [Last Updated On: August 11th, 2022] [Originally Added On: August 11th, 2022]
- The Brazilian Scientists Inventing An mRNA Vaccine And Sharing The Recipe : Short Wave - NPR [Last Updated On: August 11th, 2022] [Originally Added On: August 11th, 2022]
- 2,000 Monkeypox Vaccine Appointments Are Available in Chicago This Weekend. Here's How to Get One - NBC Chicago [Last Updated On: August 11th, 2022] [Originally Added On: August 11th, 2022]
- 'Vaccine fatigue' could hit autumn Covid boosters | News | The Sunday Times - The Times [Last Updated On: August 28th, 2022] [Originally Added On: August 28th, 2022]
- Q&A: The new COVID vaccine booster is coming. Should you get it? - The Lawton Constitution [Last Updated On: August 28th, 2022] [Originally Added On: August 28th, 2022]
- Former CRH surgeon who survived polio disheartened by vaccination lapses - The Republic [Last Updated On: August 28th, 2022] [Originally Added On: August 28th, 2022]
- 'Only the beginning': Hundreds protest Western University vaccine mandate - CBC.ca [Last Updated On: August 28th, 2022] [Originally Added On: August 28th, 2022]
- Vaccine hesitancy and trust in health experts: Shifting the focus - Medical News Today [Last Updated On: August 28th, 2022] [Originally Added On: August 28th, 2022]
- I Was There When: AI helped create a vaccine - MIT Technology Review [Last Updated On: August 28th, 2022] [Originally Added On: August 28th, 2022]
- The USDA is sprinkling fish-flavored vaccines from the sky to fight rabies - CNN [Last Updated On: August 28th, 2022] [Originally Added On: August 28th, 2022]
- COVID-19 Vaccines | FDA [Last Updated On: August 28th, 2022] [Originally Added On: August 28th, 2022]
- Novavax COVID-19 vaccine available for ages 12 and up; CDC Community Level back at Low - Communications and Outreach - New Hanover County [Last Updated On: August 28th, 2022] [Originally Added On: August 28th, 2022]
- Vaccine Definition & Meaning - Merriam-Webster [Last Updated On: August 28th, 2022] [Originally Added On: August 28th, 2022]
- National health agency apologises over Covid vaccine ads it was ordered to remove - RNZ [Last Updated On: September 3rd, 2022] [Originally Added On: September 3rd, 2022]
- Editorial: How Jewish space lasers and vaccine nanobots seized the brains of GOP voters - St. Louis Post-Dispatch [Last Updated On: September 3rd, 2022] [Originally Added On: September 3rd, 2022]
- Novel HER2-hICD Vaccine to be Investigated for Treatment of HER2-Low Breast Cancer - Targeted Oncology [Last Updated On: September 3rd, 2022] [Originally Added On: September 3rd, 2022]
- Brazilian Covid vaccine to be tested in humans in 2023 - The Brazilian Report [Last Updated On: September 3rd, 2022] [Originally Added On: September 3rd, 2022]
- A Review on the Use of the HPV Vaccine in the Prevention of Cervical Cancer - Cureus [Last Updated On: September 3rd, 2022] [Originally Added On: September 3rd, 2022]
- City Offering Second Doses of Monkeypox Vaccine to New Yorkers and Begin Accepting Walk-In Appointments - nyc.gov [Last Updated On: September 3rd, 2022] [Originally Added On: September 3rd, 2022]
- Monkeypox vax has disproportionately gone to white Philadelphians. This clinic sought to balance that. - The Philadelphia Inquirer [Last Updated On: September 3rd, 2022] [Originally Added On: September 3rd, 2022]
- Hopeful New Entry In The Race For A Universal Covid Vaccine - Forbes [Last Updated On: September 3rd, 2022] [Originally Added On: September 3rd, 2022]
- Study raises concerns about the effectiveness of the monkeypox vaccine - STAT [Last Updated On: September 3rd, 2022] [Originally Added On: September 3rd, 2022]
- newsroom.heart.org [Last Updated On: September 3rd, 2022] [Originally Added On: September 3rd, 2022]
- Did the affordable, no-patent COVID vaccine Corbevax live up to its promise? : Goats and Soda - NPR [Last Updated On: September 3rd, 2022] [Originally Added On: September 3rd, 2022]
- In CDC Survey of Over 13,000 Children, More Than Half Had 'Systemic Reaction' After COVID-19 Vaccine - The Epoch Times [Last Updated On: September 6th, 2022] [Originally Added On: September 6th, 2022]
- Department of Health working with community to administer monkeypox vaccines - Honolulu Star-Advertiser [Last Updated On: September 6th, 2022] [Originally Added On: September 6th, 2022]
- Fact check: Post-vaccine hospitalization odds not 3 times higher as ex-Japan PM claimed - The Mainichi - The Mainichi [Last Updated On: September 6th, 2022] [Originally Added On: September 6th, 2022]
- Impact of vaccinia virus-based vaccines on the 2022 monkeypox virus outbreak - News-Medical.Net [Last Updated On: September 6th, 2022] [Originally Added On: September 6th, 2022]
- Microsoft and Unicef drive Covid-19 vaccine roll-out with COVAX platform - Technology Record [Last Updated On: September 6th, 2022] [Originally Added On: September 6th, 2022]
- School Mask, Vaccine Mandates Are Mostly Gone. But What if the Virus Comes Back? - The 74 [Last Updated On: September 6th, 2022] [Originally Added On: September 6th, 2022]
- Immunogenicity and safety of an inactivated whole-virus COVID-19 vaccine (VLA2001) compared with the adenoviral vector vaccine ChAdOx1-S in adults in... [Last Updated On: September 6th, 2022] [Originally Added On: September 6th, 2022]
- Getting a Grip on Influenza: The Pursuit of a Universal Vaccine (Part 4) - Forbes [Last Updated On: September 7th, 2022] [Originally Added On: September 7th, 2022]
- Why So Few Young Kids Are Vaccinated against COVIDAnd How to Change That - Scientific American [Last Updated On: September 7th, 2022] [Originally Added On: September 7th, 2022]
- UK Travel Vaccine Market Report 2022: Increasing Travel and Tourism & Growing Incidences of Infectious Diseases Fuel Sector -... [Last Updated On: September 7th, 2022] [Originally Added On: September 7th, 2022]
- At long last, we might have an HIV vaccine - Big Think [Last Updated On: September 7th, 2022] [Originally Added On: September 7th, 2022]
- The associations between vaccination status, type, and time since vaccination with lineage identity during the emergence of new SARS-CoV-2 variants -... [Last Updated On: September 7th, 2022] [Originally Added On: September 7th, 2022]
- Needle-less COVID-19 vaccine developed at Washington University approved for use in India - KSDK.com [Last Updated On: September 10th, 2022] [Originally Added On: September 10th, 2022]
- Study: COVID-19 Vaccine Prevented Approximately 27 Million Infections in US Adults - Pharmacy Times [Last Updated On: September 10th, 2022] [Originally Added On: September 10th, 2022]
- Health System Warns Exemptions to COVID Vaccines May Expire With New Options - Medpage Today [Last Updated On: September 10th, 2022] [Originally Added On: September 10th, 2022]
- Does Moderna's vaccine IP lawsuit herald the end of the pandemic? - Medical Marketing and Media [Last Updated On: September 10th, 2022] [Originally Added On: September 10th, 2022]
- The Unintended Consequences of COVID-19 Vaccine Policy The Wire Science - The Wire Science [Last Updated On: September 10th, 2022] [Originally Added On: September 10th, 2022]
- Astrocytes, the Covid vaccine and the 2021 classification - Brain Tumour Research [Last Updated On: September 18th, 2022] [Originally Added On: September 18th, 2022]
- Nearly 50 Members of Congress Call on Pentagon to End Military Vaccine Mandate - The Epoch Times [Last Updated On: September 18th, 2022] [Originally Added On: September 18th, 2022]
- New Omicron-fighting Covid vaccine supplied with flimsy needles across Scotland to get replacement syringes - STV News [Last Updated On: September 18th, 2022] [Originally Added On: September 18th, 2022]
- Is There A Minimum Age for the Shingles Vaccine? - Healthline [Last Updated On: September 18th, 2022] [Originally Added On: September 18th, 2022]
- Detection of circulating vaccine derived polio virus 2 (cVDPV2) in environmental samples the United Kingdom of Great Britain and Northern Ireland and... [Last Updated On: September 18th, 2022] [Originally Added On: September 18th, 2022]
- 850 more unvaxxed NYC teachers, aides fired for not complying with mandate - New York Post [Last Updated On: September 18th, 2022] [Originally Added On: September 18th, 2022]
- 'India's vaccine growth story' book review: Far from being a dry collection of facts and figures - The New Indian Express [Last Updated On: September 18th, 2022] [Originally Added On: September 18th, 2022]
- Health care workers appeal dismissal of lawsuit over Maine's vaccine mandate - Kennebec Journal and Morning Sentinel [Last Updated On: September 18th, 2022] [Originally Added On: September 18th, 2022]
- Department of Health Expands Eligibility for the Monkeypox Vaccine - Anne Arundel County Department of Health [Last Updated On: September 25th, 2022] [Originally Added On: September 25th, 2022]
- Could This Be Pfizer's Next Billion-Dollar Vaccine? - The Motley Fool [Last Updated On: September 25th, 2022] [Originally Added On: September 25th, 2022]
- Many Vaccinated Youth Who Suffered Heart Inflammation Had Abnormal MRI Results Months Later: CDC Study - The Epoch Times [Last Updated On: September 25th, 2022] [Originally Added On: September 25th, 2022]
- Second vaccine doses to be offered to those at highest risk from monkeypox - GOV.UK [Last Updated On: September 25th, 2022] [Originally Added On: September 25th, 2022]
- Structure of the malaria vaccine candidate Pfs48/45 and its recognition by transmission blocking antibodies - Nature.com [Last Updated On: September 25th, 2022] [Originally Added On: September 25th, 2022]
- Coronavirus Roundup: A CDC Team Is Honored for Its Vaccine Distribution Work - GovExec.com [Last Updated On: September 25th, 2022] [Originally Added On: September 25th, 2022]
- Everything to know about the Monkeypox vaccine | Health - Red and Black [Last Updated On: September 25th, 2022] [Originally Added On: September 25th, 2022]
- The U.S. ordered 171 million updated COVID booster shots but only 4.4 million went into arms as Biden says the pandemic is over - Fortune [Last Updated On: September 25th, 2022] [Originally Added On: September 25th, 2022]
- Why mosquitoes were the vaccinators in a new malaria vaccine trial : Goats and Soda - NPR [Last Updated On: September 25th, 2022] [Originally Added On: September 25th, 2022]
- Lyme disease is on the rise. Why is there still no vaccine? - AAMC [Last Updated On: September 25th, 2022] [Originally Added On: September 25th, 2022]
- Government of Canada announces funding for advancements in mRNA vaccine technology at the University of British Columbia - Canada NewsWire [Last Updated On: October 3rd, 2022] [Originally Added On: October 3rd, 2022]
- 130 people have received incorrect doses of COVID-19 vaccines: MOH - CNA [Last Updated On: October 3rd, 2022] [Originally Added On: October 3rd, 2022]
- Health unit hosts pop-up vaccine clinics throughout the week - BradfordToday [Last Updated On: October 3rd, 2022] [Originally Added On: October 3rd, 2022]
- Doctor who gave anti-vaccine speech in front of effigies of officials being hanged faces discipline hearing - CBC.ca [Last Updated On: October 3rd, 2022] [Originally Added On: October 3rd, 2022]
- What's really happening with global vaccine access? - Gavi, the Vaccine Alliance [Last Updated On: October 3rd, 2022] [Originally Added On: October 3rd, 2022]
- Study confirms link between COVID-19 vaccination and temporary increase in menstrual cycle length - National Institutes of Health (.gov) [Last Updated On: October 3rd, 2022] [Originally Added On: October 3rd, 2022]